Jiangsu Hengrui Medicine Full Year 2024 Earnings: Beats Expectations

Simply Wall St · 03/31 22:07

Jiangsu Hengrui Medicine (SHSE:600276) Full Year 2024 Results

Key Financial Results

  • Revenue: CN¥28.0b (up 23% from FY 2023).
  • Net income: CN¥6.34b (up 47% from FY 2023).
  • Profit margin: 23% (up from 19% in FY 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥1.00 (up from CN¥0.68 in FY 2023).
earnings-and-revenue-growth
SHSE:600276 Earnings and Revenue Growth March 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jiangsu Hengrui Medicine Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.4%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 11% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Jiangsu Hengrui Medicine's balance sheet and an in-depth analysis of the company's financial position.